Disease relevance of Paratect

• After a 4-week holding period to allow for maturation of acquired gastrointestinal nematodes, 5 calves from each group were administered a therapeutic dose (10 mg/kg of body weight) of morantel tartrate [1].
• Effectiveness of a slow-release, morantel tartrate anthelmintic bolus for controlling parasitic gastroenteritis in replacement dairy heifers [2].
• Low level feed administration of morantel tartrate in the prophylaxis of experimental nematode infections in lambs and calves [3].

High impact information on Paratect

• A novel intraruminal bolus developed for the sustained delivery of the anthelmintic morantel tartrate was evaluated in the seasonal control of parasitic gastroenteritis in first season grazing calves [4].
• In order to study the reliability of the larval paralysis test as an in vitro assay for the detection of resistance of nematodes to levamisole and morantel tartrate, the influence of different parameters was evaluated using resistant and susceptible Ostertagia ostertagi strains [5].
• Cows in treated herds were given morantel tartrate in May, June, and July, and cows in control herds were given a placebo of ground corn, wheat bran, and barley; both products were administered at 1 kg/1000 kg body weight [6].
• Effect of the morantel sustained-release bolus, used during one grazing season, on the sensitivity of Ostertagia and Cooperia to morantel tartrate in calves [7].
• The efficacy of morantel tartrate when administered on a continuous basis directly into the rumen/reticulum of cattle, either by a cannula or from a specially designed device, was evaluated against gastrointestinal parasites under laboratory conditions [8].

Chemical compound and disease context of Paratect

• The evaluation of data on 15th day of the administration showed that 2 g/kg of powder, its equivalent amount of methanol extract and 0.01 g/kg of morantel tartrate are equally effective and safe in treating natural gastrointestinal nematode infection of the local goats [9].

Biological context of Paratect

• The pharmacokinetics and gastrointestinal distribution of morantel tartrate release from a sustained release trilaminate bolus in cattle were investigated over a 98-day period post-treatment [10].
• Eleven lactating cows of various ages, periods of lactation, and known milk production were orally dosed with the bolus formulation of morantel tartrate with an actual dose range of 8.4-9.8 mg/kg body weight [11].
• The strain selected by both tiabendazole and morantel tartrate had a significantly higher LD50 against thiabendazole, morantel tartrate and levamisole than did the other three strains [12].

Anatomical context of Paratect

• High concentrations of morantel tartrate were found in ruminal, abomasal and ileal fluids and feces over 98 days post-treatment [10].

Associations of Paratect with other chemical compounds

• A herd of goats naturally infected with lungworm and gastrointestinal nematodes was divided into three groups and treated with either morantel tartrate or fenbendazole at strategic periods, i.e. in June (at pre-mating), in November (at pre-kidding) and in January (at early lactation) or left untreated [13].
• Merino and Border Leicester cross Merino sheep, nine months old, were infected with 10,000 third stage larvae of both Trichostrongylus colubriformis (PF4) and Ostertagia circumcincta/O trifurcata (PF5), known to have varying degrees of resistance to levamisole, morantel tartrate and thiabendazole [14].

Analytical, diagnostic and therapeutic context of Paratect

• In April 1985, the calves comprising the treatment group each received an MSRT designed to release morantel tartrate continuously for 90 days while those of the control group remained unmedicated [15].
• In horses dosed with morantel tartrate egg counts were reduced to zero by 7 days after treatment [16].
• Morantel tartrate concentrations were measured by HPLC after extraction and clean-up [10].
• Morantel could not be detected (< 0.05 microgram/ml) in the plasma of cattle or goats following the oral administration of morantel tartrate at a dose rate of 10 mg/kg bodyweight [17].

References